Senior Director, Search & Evaluation Late TA Lead, Immunology

CSL

2d•Hybrid

About The Position

CSL is expanding its external innovation capability, and we're looking for a Senior Director of Search & Evaluation to help shape the future of our Immunology portfolio. We are seeking a Senior Director of Search & Evaluation to lead strategic sourcing and evaluation of later-stage external clinical assets in Immunology. This leader will focus on opportunities from Phase 2 through marketed drugs, requiring deep clinical expertise, strong engagement with external Key Opinion Leaders (KOLs) and clinical investigators, and a keen understanding of evolving standards of care. The role is critical to shaping our portfolio through high-impact partnerships and transactions. To be hybrid-based onsite (3 days a week) at one of our R&D hub sites: Zurich (CH), Maidenhead (UK), Waltham (US), King of Prussia (US). This position cannot be held remotely

Requirements

15+ years in biopharma with significant experience in clinical development, external innovation, or business development.
Advanced degree required (MD, PhD, or equivalent).
Deep clinical expertise in Immunology
Proven track record of sourcing and closing late-stage deals and engaging with KOLs and clinical networks.
Strong understanding of regulatory pathways, market access, and competitive standards of care.

Responsibilities

Serve as the senior S&E leader within the Therapy Area Leadership Team, influencing therapeutic strategy and integrating late-stage external innovation priorities into portfolio planning.
Lead proactive sourcing efforts for Phase 2 to marketed assets, identifying opportunities that align with TA strategy and unmet medical needs.
Co-lead internal meetings (with Early Search Lead) focused on evaluating and prioritizing New Product Opportunities (NPOs) within Immunology. NPO meetings are strategic checkpoints where cross-functional teams review potential assets identified by Search and decide whether to advance them for further due diligence and deal negotiations.
Engage extensively with external KOLs, clinical investigators, and networks to validate asset potential, understand trial designs & clinical endpoints, and anticipate competitive dynamics.
Maintain deep awareness of changing standards of care and competitive landscapes to inform sourcing priorities and deal strategy.
Drive cross-functional due diligence for late-stage assets, coordinating clinical, regulatory, commercial, and market access assessments to support governance decisions.
Partner closely with BD and Regional Ecosystem Leads to advance high-priority opportunities through negotiation and deal close, ensuring seamless handoff and execution.
Represent the TA externally, leading sourcing activities at specialized conferences and building relationships with pharma, biotech, and clinical communities.